Meanwhile, BC cell lines with low sgIMMT efficiency exhibited increased sensitivity to MK-1775 (Fig. 10C), luminespib (Fig. 10D), ulixertinib (Fig. 10E), camptothecin (Fig. 10F), wee1 inhibitors (Fig. 10G), and pyridostatin (Fig. 10H). Here, WEE1 is linked to breast cancer.